NEUROPROTECTIVE PROPERTIES OF SELECTIVE PPAR GAMMA AGONIST LY554862

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: To assess neuroprotective properties of the PPAR GAMMA AGONIST LY554862 in treating Parkinson's disease. Our laboratory has recently shown that chronic oral administration of pioglitazone induces modest neuroprotection against MPTP intoxication in a primate model. Based on this information we continued to investigate PPAR-¿ activation as a possible therapeutic target for PD. This research used WNPRC Assay Services and is precursor work to nonhuman primate studies. A publication is in preparation.